

Recommendations from York and Scarborough Medicines Commissioning Committee March 19th 2014

Drug and Brand name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact S&R CCG	Potential full year cost impact VOYCCG
Insulin degludec (Tresiba [®])	Treatment of diabetes mellitus in adults	Approved	For use in patients for whom insulin U500 would otherwise be prescribed and for patients with significant nocturnal hypoglycaemia.	Amber – specialist initiation	£4,662-£9,324 Year 1 Manufacturer data and is offset against insulin glargine	£13,320-£26,640 Year 1 Manufacturer data and is offset against insulin glargine
Insulin 500 units in 1mL (Humulin R [®])	Treatment of diabetes mellitus in adults (unlicensed)	Non formulary	Decommissioned – this treatment option is replaced by insulin degludec	Black	Nil – replaced by insulin degludec	Nil – replaced by insulin degludec
Lixisenatide (Lyxumia [®])	Adults - Type 2 diabetes	Approved	Approved as first line agent within this class of drugs when indicated as per NICE. Other treatment choices (liraglutide, exanatide) to be discussed as part of the diabetes formulary review.	Green	Cost savings will be made. See Table 1	Cost savings will be made. See Table 1
Tadalafil 5mg (Cialis [®])	Benign prostatic hyperplasia	Not approved	Tadalafil is not routinely commissioned. No evidence that it is more effective than other formulary drugs for this clinical indication	Black	Nil	Nil
Hydrocortisone modified release (Plenadren [®])	Adrenal insufficiency in adults	Not approved	Hydrocortisone MR is not routinely commissioned. Robust clinical and cost evidence fails to demonstrate clear advantages over standard hydrocortisone.	Black	Nil	Nil
Linaclotide (Constella [®])	Adults with moderate to severe irritable bowel syndrome with constipation	Approved	Restricted to use after antispasmodics, laxatives and antidepressants have failed or due to inadequate response	Green	1 patient* £488 *based on Gastroenterologist D&T application local numbers	3 patients* £1,464 *based on Gastroenterologist D&T application local numbers

Fluticasone and azelastine nasal spray (Dymista)	Relieve symptoms of moderate to severe seasonal and perennial allergic rhinitis where treatment monotherapy is not sufficient	Not approved	Not routinely commissioned. Prescribing a low cost antihistamine and steroid nasal spray as single items represents better overall value to the NHS.	Black	Nil	Nil
Botulinum A toxin (Various brands available)	Anal fissures (unlicensed indication)	Approved	CCG commissioned PbR excluded drug. Review of existing policy.	Red	No new additional activity expected. Review of existing policy.	No new additional activity expected. Review of existing policy.
Botulinum A toxin (Various brands available)	Hyperhidrosis	Approved	CCG commissioned PbR excluded drug. Review of existing policy.	Red	No new additional activity expected. Review of existing policy.	No new additional activity expected. Review of existing policy.
Delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol oromucosal spray (Sativex®)	Moderate to severe spasticity due to multiple sclerosis in adults who have failed other anti-spasticity medication	Not approved	Not routinely commissioned due to lack of robust clinical and cost effectiveness. Review of existing policy.	Black	Nil	Nil
Co-careldopa 2000mg/500mg intestinal gel (Duodopa®)	Advanced levodopa responsive Parkinson's Disease after other agents fail to give satisfactory results	Not approved	Not routinely commissioned, the clinical and cost effectiveness case was not sufficient to recommend its use	Black	Nil	Nil

Midodrine (unlicensed)	Postural hypotension	Approved	Restricted use after failure of standard non pharmacological measures and fludrocortisone. Treatment to be initiated by the specialist to evaluate effectiveness as outlined in policy.	Amber – specialist initiation	This is an unlicensed drug – a “special” and as such it is not possible to predict costs. Anticipated patient use is very low e.g. 1-2 new patients per annum. Last 12 month spend is £1,846	This is an unlicensed drug – a “special” and as such it is not possible to predict costs. Anticipated patient use is very low e.g. 1-2 new patients per annum. Last 12 month spend is £13,498
Flutter device	Oscillating positive pressure device to improve/ease airway clearance	Approved		Amber – specialist initiation	£40.50/unit	£40.50/unit
Sildenafil chewable tablets (Nipatra®)	Men with erectile dysfunction	Not approved	This formulation of tablet is not routinely commissioned. Generic sildenafil tablets are an option for patients eligible for treatment as per NHS criteria.	Black	Nil	Nil
Outstanding NICE TAGs						
TA297 Ocriclasmin (Jetrea®) October 2013	Approved by NICE for vitreomacular traction		http://publications.nice.org.uk/ocriplasmin-for-treating-vitreomacular-traction-ta297	Red	£3,954 CSU NICE Update 8	£13,263 CSU NICE Update 8
TA298 Ranibizumab November 2013	Approved by NICE as an option for treating visual impairment due to choroidal neovascularisation secondary to myopia when the manufacturer provides the drug with the discount agreed in the patient access scheme		http://publications.nice.org.uk/ranibizumab-for-treating-choroidal-neovascularisation-associated-with-pathological-myopia-ta298	Red	See attached documents	

<p>TA301 Fluocinolone acetonide intravitreal implant November 2013</p>	<p>Approved by NICE as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if:</p> <ul style="list-style-type: none"> • The implant is to be used in an eye with an intraocular (pseudophakic) lens and • The manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme 	<p>http://guidance.nice.org.uk/TA301</p>	<p>Red</p>	<p>See attached documents</p>
--	---	--	------------	-------------------------------

Table 1: Comparative savings of formulary choice agent lixisenatide compared with alternative commissioned agents within the therapeutic class.

Drug	Dose	Annual cost per patient	Annual cost per 100 new patients	Potential savings/100 new patients against competitor
Lixisenatide	20mcg Once daily	£704 a year	£70,400	
Exenatide (Byetta)	5 - 10 mcg twice daily	£830.25	£83,025	£12,625
Exenatide (Byduren)	2 mg once WEEKLY	£953.68	£95,368	£24,968
Liraglutide Patent expires 2022	1.2 mg once daily (1.8mg not recommended)	£954.84	£95,484	£25,084